Abbvie
Glenmark gains 3% on $700 mn upfront payment from AbbVie licensing deal
Glenmark shares rose 3% after confirming receipt of $700 million from AbbVie under a global licensing deal for ISB 2001, with milestone payments of up to $1.2 billion
 "Glenmark gains 3% on $700 mn upfront payment from AbbVie licensing deal")
Action likely against AbbVie executive who signed self-declaration
Pharma cos and docs say medical conferences have declined since March after UCPMP was notified
 "Action likely against AbbVie executive who signed self-declaration")
Biosimilar Humira likely to boost US revenues for Biocon Biologics
Analysts, however, feel that together with upcoming Aspart (insulin) and vaccines, Hulio will help drive BBL's revenues from the current $1 billion to around $1.65 billion by FY25
 "Biosimilar Humira likely to boost US revenues for Biocon Biologics")
Shot of Hope: Equal access a hurdle after race to coronavirus vaccine
The second of a two-part series examines challenges linked to IPR and monopoly once Covid-19 vaccine is created
 "Shot of Hope: Equal access a hurdle after race to coronavirus vaccine")
AbbVie strikes $63-billion deal for merger with botox-maker Allergan
The price tag caused some heartburn on Wall Street, with AbbVie declining as much as 16% to $66 at 1:38 p.m. in New York
 "AbbVie strikes $63-billion deal for merger with botox-maker Allergan")
AbbVie makes USD 63B bid for Botox maker Allergan
The specialty drug company AbbVie will spend USD 63 billion to acquire Allergan, the maker of Botox and other cosmetic treatments. The two pharmaceutical companies have little in common, save for a desire to reinvigorate growth that has sputtered. Shares of AbbVie are down 16 per cent over the past year and shares of Allergan are down 24 per cent. "This is a transformational transaction for both companies and achieves unique and complementary strategic objectives," said AbbVie CEO and Chairman Richard Gonzalez in a prepared statement Tuesday. "The combination of AbbVie and Allergan increases our ability to continue to deliver on our mission to patients and shareholders." The maker of the global blockbuster immune disorder treatment Humira will pay USD 120.30 in cash and a portion of AbbVie stock for each Allergan share. That amounts to USD 188.24 per share, or a 45 per cent premium to Allergan's closing price Monday. AbbVie is facing the expiration of patent protection for Humira,
 "AbbVie makes USD 63B bid for Botox maker Allergan")
